MARKET

DBVT

DBVT

DBV Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.11
-0.02
-0.39%
Closed 16:00 09/17 EDT
OPEN
5.12
PREV CLOSE
5.13
HIGH
5.13
LOW
5.06
VOLUME
51.79K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
1.350
MARKET CAP
562.22M
P/E (TTM)
-4.3006
1D
5D
1M
3M
1Y
5Y
European ADRs Rise 1% Monday as Energy Giants Gain, Pharma Retreats
MT Newswires · 4d ago
Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021
Monthly information regarding the total number of voting rights and total number of shares of the Company as of August 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 00...
GlobeNewswire · 09/08 20:00
DBV Technologies to Participate at Upcoming Investor Conferences
Montrouge, France, August 31, 2021 DBV Technologies to Participate at Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that DBV Tech...
GlobeNewswire · 08/31 05:30
Beyond Air® Announces CFO Transition
GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, i...
GlobeNewswire · 08/20 20:15
Beyond Air Names New CFO
MT Newswires · 08/20 16:31
Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021
Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010...
GlobeNewswire · 08/09 20:30
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
AMF REGULATED INFORMATIONMontrouge, France, August 6, 2021 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical compa...
GlobeNewswire · 08/06 20:30
European ADRs Move Higher in Tuesday Trading
MT Newswires · 08/03 11:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DBVT. Analyze the recent business situations of DBV Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DBVT stock price target is 10.92 with a high estimate of 13.90 and a low estimate of 7.94.
EPS
Institutional Holdings
Institutions: 96
Institutional Holdings: 39.52M
% Owned: 35.92%
Shares Outstanding: 110.02M
TypeInstitutionsShares
Increased
11
34.73K
New
5
7.36K
Decreased
12
485.18K
Sold Out
2
20.71K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
Pierre-Henri Benhamou
Chief Operating Officer
David Schilansky
Executive Vice President/General Counsel
Joan Schmidt
Chief Scientific Officer
Hugh Sampson
Vice President - Research & Development
Lucie Mondoulet
Vice President - Business Development
Nathalie Donne
Director of Marketing
Veronique Foutel
Other
Wence Agbotounou
Other
Bertrand Dupont
Other
Pascale Ehouarn
Other
Laurent Martin
Director
Michel de Rosen
Director
Mailys Ferrere
Director
George Horner
Director
Didier Hoch
Director
Chahra Louafi
Director
Rafaele Tordjman
No Data
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers kinds of DBV Technologies SA stock information, including NASDAQ:DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.